Skip to content

Study · Not a test of the peptide alone · 2024

2 results

Effects of GLP-1 receptor agonists on the degree of liver fibrosis and CRP in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: A systematic review and meta-analysis.

Fang L, Li J, Zeng H, Liu J

Primary care diabetes30 Mar 2024Cited by 26 (Europe PMC)

PMID38555202 (opens in a new tab)DOI10.1016/j.pcd.2024.03.005 (opens in a new tab)PepBankPUB-38555202
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In patients with NAFLD or NASH, pooled GLP-1 RAs (including liraglutide) significantly improved histologic resolution of NASH with no worsening of liver fibrosis (2 RCTs).

    In plain wordsIn people with fatty liver disease, GLP-1 drugs such as liraglutide improved resolution of NASH without worsening liver scarring in 2 trials.

    Peptide
    Liraglutide
    Outcome
    IncreaseHistologic resolution of NASH with no worsening of liver fibrosis
    Study

    n: not reported in source

    Comparator
    Placebo or active drug
    Outcome group
    Liver fat and liver function · Liver

    Measurements

    WMD
    4.08 NA
    histologic resolution of NASH, 2 RCTs

    Source sentences

    Summary
    This study found that the effect of GLP-1RAs on histologic resolution of NASH with no worsening of liver fibrosis (n=2 RCTs; WMD:4.08, 95%CI 2.54-6.56, p < 0.00001) has statistically significant.
    1 context sentence
    Summary · context
    We included 16 placebo-controlled or active drug-controlled randomized controlled trials (involving 2178 patients) that used liraglutide, exenatide, dulaglutide, or semaglutie in the treatment of NAFLD or NASH, as measured by liver biopsy or imaging techniques.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In patients with NAFLD or NASH, pooled GLP-1 RAs (including liraglutide) significantly lowered CRP (7 RCTs).

    In plain wordsIn people with fatty liver disease, GLP-1 drugs such as liraglutide lowered the inflammation marker CRP in 7 trials.

    Peptide
    Liraglutide
    Outcome
    DecreaseC-reactive protein (CRP)
    Study

    n: not reported in source

    Comparator
    Placebo or active drug
    Outcome group
    Inflammation markers · Immune and inflammation

    Measurements

    WMD
    −0.41 NA
    CRP, 7 RCTs

    Source sentences

    Summary
    At the same time, GLP-1RAs affected CRP (n = 7 RCTs; WMD:-0.41, 95% CI-0.78 to -0.04, p =0.002) and other serological indicators were significantly improved.
    1 context sentence
    Summary · context
    We included 16 placebo-controlled or active drug-controlled randomized controlled trials (involving 2178 patients) that used liraglutide, exenatide, dulaglutide, or semaglutie in the treatment of NAFLD or NASH, as measured by liver biopsy or imaging techniques.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.